Compare CAF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAF | ALLO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | CAF | ALLO |
|---|---|---|
| Price | $17.24 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 63.6K | ★ 2.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.63 | $0.86 |
| 52 Week High | $14.38 | $3.78 |
| Indicator | CAF | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 67.18 | 62.29 |
| Support Level | $17.05 | $1.41 |
| Resistance Level | $17.44 | $1.52 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 88.65 | 86.96 |
Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.